Drug profile

The FDA adverse-event record for Pancreatic Enzyme

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Pancreatic Enzyme. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
23.1%
death-coded share
Dog
most-reported species
4
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
3
Deaths Reported
23.1%
Death Rate

Active Ingredients

Pancreatic Enzyme

Administration Routes

OralUnknown

Species Affected

Dog 12
Cat 1

Most Affected Breeds

Shepherd Dog - German 3
Dachshund (unspecified) 2
Spaniel - Cocker American 1
Retriever - Golden 1
Chihuahua 1
Newfoundland 1
Sheepdog - Shetland 1
Shepherd (unspecified) 1
American Curl Shorthair 1
Poodle (unspecified) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 4
Vomiting 4
Weakness 3
Leucopenia NOS 3
Inappetence 3
Diarrhoea 2
Circling - neurological disorder (see also 'Behavioural disorders') 2
Renal disorder NOS 2
Other abnormal test result NOS 2
Elevated blood urea nitrogen (BUN) 2
Elevated alanine aminotransferase (ALT) 2
Elevated serum alkaline phosphatase (SAP) 2

Outcome Breakdown

Recovered/Normal
4 (30.8%)
Ongoing
4 (30.8%)
Euthanized
2 (15.4%)
Outcome Unknown
2 (15.4%)
Died
1 (7.7%)

Pancreatic Enzyme Adverse Event Insights

13 reports name Pancreatic Enzyme; 3 recorded a death outcome (23.1% of reported events, not a population-level mortality rate). Active ingredient: Pancreatic Enzyme. Administration routes: Oral, Unknown.

By species: Dog (12 reports), Cat (1 reports). By breed: Shepherd Dog - German (3), Dachshund (unspecified) (2), Spaniel - Cocker American (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (4), Vomiting (4), Weakness (3), Leucopenia NOS (3). Outcome, 13 coded reports: Recovered/Normal leads at 30.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.